Adrenocorticotropic Hormone Secreting Carcinoma of the Pancreas: A Case Report
Josh Bleicher,1,* Sarah Lombardo,1 Stacie Carbine,1,2 Dmitri Kapitonov,2,3 Maria A. Pletneva,2,3 and Sean J. Mulvihill1,2

Abstract
Introduction: Adrenocorticotropic hormone (ACTH) secreting pancreatic neuroendocrine neoplasms (pNENs) are rare. The clinical and biological behavior of pNENs is poorly understood. Patients often present at an advanced stage of disease and outcomes remain poor. This report demonstrates a case of ectopic Cushing’s syndrome secondary to an ACTH-producing pancreatic neuroendocrine carcinoma (pNEC).

Case report: A 54-year-old woman presented with rapidly progressive Cushing’s syndrome complicated by hypertension and acute heart failure. This was ultimately found to be secondary to a metastatic ACTH-producing pNEC. She underwent laparoscopic distal pancreatectomy and splenectomy with hepatic metastasectomy as primary treatment. She had rapid correction of her endocrine abnormalities and associated physiological abnormalities. She had progressive hepatic metastases found on imaging at 3 months, but remained free of significant endocrine abnormalities for 9 months after surgery. Her disease did recur and she died of complications associated with her disease at 1 year after her surgery.

Conclusion: ACTH-producing pNEN is a very rare disease with a poor prognosis. Robust evidence to guide treatment decisions is limited. This report suggests that aggressive surgical management of primary and metastatic lesions for management of this disease is reasonable, consistent with prior case reports. Control of endocrine abnormalities offers the best opportunity for prolonged survival, and an aggressive surgical approach can achieve this goal. The patient presented had control of endocrine abnormalities after surgery for 9 months before symptomatic disease recurrence.

Keywords: neuroendocrine tumor; pancreatic endocrine neoplasm; adrenocorticotropic hormone

Introduction
Pancreatic neuroendocrine neoplasms (pNENs) account for just 1–2% of pancreatic neoplasms.1 The reasons underpinning the variable clinical expression of pNENs are poorly understood. Median survival is 42 months and the majority (64%) of patients present with distant disease at the time of diagnosis.2 Although about half of pNENs are nonfunctional, others secrete hormones causing well-defined clinical syndromes. A very rare presentation is secretion of adrenocorticotropic hormone (ACTH), reported only in a number of case reports and small series.3–4 Ectopic ACTH production is responsible for ~10–20% of cases of Cushing’s syndrome, with the majority related to lung tumors.5 A pancreatic source has been reported in 15% of patients with ectopic ACTH production.5 In this report, we present a case of ectopic Cushing’s syndrome secondary to an ACTH-producing pancreatic neuroendocrine carcinoma (pNEC) with an aggressive phenotype.

Case Report
A 54-year-old woman with history of hypertension and newly diagnosed type II diabetes mellitus developed facial flushing, muscle weakness, labile blood pressures,
lower extremity edema, and uncontrollable hyperglycemia despite maximal medical therapy. She then developed acute heart failure requiring inpatient admission. On admission, physical examination showed classic stigmata of Cushing’s syndrome, including easy bruisability, moon facies, a buffalo hump, and abdominal striae (Fig. 1). Brain magnetic resonance imaging showed no sellar or suprasellar mass. Random cortisol level was 61 μg/dL (normal 6–23 μg/dL), random ACTH level was 223 pg/mL (6–58 pg/mL), and 24-h
urinary cortisol secretion was elevated. She underwent inferior petrosal sinus sampling with no significant central to peripheral ACTH concentration gradient, leading to a diagnosis of ectopic ACTH syndrome. Abdominal imaging, including ultrasonography, computed tomography (CT), and ultimately positron emission tomography (PET)-CT, identified a 3.4 × 2.9 cm hypermetabolic mass in the pancreatic tail with abnormal peripancreatic lymph nodes and a hepatic lesion concerning for metastatic disease (Fig. 2). Endoscopic ultrasonography with fine needle aspiration of the pancreatic mass revealed a pNEN with immunohistochemical stains positive for ACTH, synaptophysin, and chromogranin.

With the diagnosis of an ACTH-producing pNEN confirmed, the patient underwent laparoscopic distal pancreatectomy and splenectomy with hepatic metastasectomy. All gross disease was resected. Histological examination revealed a high-grade neuroendocrine carcinoma without features of small or large cell involving pancreas, liver, and 6 of 16 lymph nodes (Fig. 3). The patient’s ACTH and cortisol levels normalized within 24 h. Her postoperative course was complicated by Ogilvie’s syndrome requiring right hemicolectomy. She subsequently recovered without other complications. She was started on lanreotide postoperatively, which she continued at the time of discharge. Imaging revealed progressive hepatic metastases 3 months after resection. She was treated with capecitabine at another institution at this time, which she continued intermittently for the next 6 months. Unfortunately, she developed recurrent symptoms of Cushing’s syndrome and heart failure at ~9 months postoperatively and died of complications related to her disease 1 year after the operation.

**Conclusion**

A 54-year-old woman was found to have rapidly progressive Cushing’s syndrome secondary to a metastatic ACTH-producing pNEN. She underwent laparoscopic distal pancreatectomy with hepatic metastasectomy. Her endocrine abnormalities rapidly resolved after
surgery; however, her disease recurred and she eventually died of complications from her disease 1 year post-operatively.

ACTH-producing pNEN is a rare disease with a poor prognosis; 5-year survival is 16–60%.\(^4,5\) Literature to guide treatment decisions is limited. Surgical resection of the primary tumor and metastatic disease provides the best opportunity to alleviate associated endocrine abnormalities.\(^6\) The extent of hypercortisolism in patients with ectopic Cushing’s syndrome is closely correlated with mortality rates.\(^5\) If medically refractory Cushing’s syndrome is present after complete surgical resection, bilateral adrenalectomy is associated with improved 2-year overall survival, although no difference in 5-year overall survival. This report suggests that aggressive surgical management of patients with ACTH-producing pNENs is reasonable. In this case, the patient’s endocrine abnormalities temporarily resolved with control of the primary tumor. Although this patient’s overall prognosis remained poor, aggressive surgical management provided control of her endocrine symptoms for 9 months and improved quality of life during this time.

**Author Disclosure Statement**

No competing financial interests exist.

**References**

1. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24:46–55.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after “Carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2017;26:3063–3072.
3. Patel FB, Khagi S, Daly KP, et al. Pancreatic neuroendocrine tumor with ectopic adrenocorticotropic hormone production: a case report and review of literature. Anticancer Res. 2013;30:6001–4005.
4. Kondo T, Matsuyama R, Ashihara H, et al. A case of ectopic adrenocorticotropic hormone-producing pancreatic neuroendocrine tumor with multiple liver metastases. Endocr J. 2010;57:229–236.
5. Davi MV, Cosaro E, Piacentini S, et al. Prognostic factors in ectopic Cush-
ing’s syndrome due to neuroendocrine tumors: a multicenter study. Eur J Endocrinol. 2017;176:451–459.
6. Finkelstein P, Sharma R, Picado O, et al. Pancreatic neuroendocrine tumors (panNETs): analysis of overall survival of nonsurgical management versus surgical resection. J Gastrointest Surg. 2017;5:855–866.